8-K: Genprex Unveils Positive Preclinical Data for Diabetes Gene Therapy GPX-002 with Novel Non-Viral Delivery System

Genprex, Inc. announced positive preclinical data for its diabetes gene therapy drug candidate, GPX-002, utilizing a novel non-viral lipid nanoparticle delivery system, presented at the 2025 American Diabetes Association 85th Scientific Sessions.

Summary

• Genprex, Inc. issued a press release announcing positive preclinical data and research from studies of GPX-002, the Company's diabetes gene therapy drug candidate.
• The data was presented by research collaborators at the 2025 American Diabetes Association (ADA) 85th Scientific Sessions in Chicago, Illinois.
• The studies employed an alternative second-generation approach using a non-viral lipid nanoparticle (LNP) delivery system.
• This exploratory research aims to determine if the novel diabetes gene therapy can be delivered non-virally, potentially allowing for repeat dosing.
• The Company believes the research demonstrates its ability to use LNPs with a nucleic acid payload to transfect cells within the islets of Langerhans via direct infusion into the biliary/pancreatic duct, replacing a viral AAV construct.
• Nine LNPs prepared with patented LipexSil lipids and a green fluorescent protein (GFP) messenger RNA (mRNA) payload were evaluated for transfection efficiency in isolated mouse Islets of Langerhans.
• Two specific LNPs showed high efficiency in transfecting alphaand beta-cells in isolated mouse Islets of Langerhans.
• An LNP made using ALX-184 with a Luciferase mRNA payload efficiently transfected pancreatic cells when injected into the mouse common bile duct, indicating successful crossing of the basement membrane.
• The same ALX-184 LNP with a GFP mRNA payload also efficiently transfected mouse Islet of Langerhans cells.
• This new research complements Genprex's ongoing preclinical studies using an adeno-associated virus (AAV) construct and focuses on optimizing next-generation constructs.

Sentiment

Score: 8

Explanation: The announcement of positive preclinical data for a novel non-viral gene therapy delivery system for diabetes is a significant positive development, establishing proof of concept and opening avenues for future development with potential benefits like repeat dosing and reduced immunogenicity. However, it is still early-stage preclinical research, and the company faces substantial risks related to clinical development, regulatory approvals, and financial stability.

Positives

• Positive preclinical data for GPX-002, Genprex's diabetes gene therapy drug candidate, was announced.
• The research established proof of concept for a novel non-viral lipid nanoparticle (LNP) delivery system for gene therapy.
• The LNP system demonstrated the ability to efficiently transfect cells within the islets of Langerhans via direct infusion.
• Two specific LNPs, prepared with patented LipexSil lipids, were highly efficient in transfecting alphaand beta-cells in isolated mouse Islets of Langerhans.
• The ALX-184 LNP successfully transfected pancreatic cells and crossed the basement membrane in mouse models.
• The non-viral delivery system offers significant potential benefits, including the ability for repeat dosing of patients to optimize treatment.
• The non-viral approach may eliminate the need for immunosuppression, as there is no immune response against LNPs.

Risks

• Genprex's ability to advance the clinical development, manufacturing, and commercialization of its product candidates in accordance with projected timelines.
• The timing and success of Genprex's clinical trials and regulatory approvals, including the anticipated effects of GPX-002 and its potential as a therapeutic approach.
• The effectiveness of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes.
• The impact and successful implementation of any strategic research and development prioritization initiatives or other strategic alternatives.
• Genprex's future growth and financial status, including its ability to maintain compliance with Nasdaq listing requirements and to continue as a going concern.
• Genprex's ability to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all.
• The performance and scalability of manufacturing by Genprex's commercial and strategic partners, including third-party vendors, suppliers, and manufacturers.
• Risks associated with Genprex's intellectual property and licenses.
• Actual results may differ materially from forward-looking statements due to various important factors and uncertainties.

Future Outlook

The Company believes these positive preclinical findings provide the necessary proof of concept to advance with additional studies for GPX-002. This research opens the door for a next-generation approach to their novel gene therapy that would allow repeat dosing of patients, which is considered potentially very important for Type 1 diabetes treatment. Genprex will continue its research with its contract development and manufacturing organization partner, focusing on evaluating potential next-generation construct optimization, in addition to ongoing preclinical studies using an AAV construct.

Management Comments

• "The Company believes the research demonstrates Genprex's ability to use a lipid nanoparticle with a nucleic acid payload to transfect cells within the islets of Langerhans via a direct infusion into the biliary duct/pancreatic duct in place of a viral AAV construct."
• "The Company believes these findings provide the proof of concept needed to move forward with additional studies and opens the door for a next generation approach of our novel gene therapy that would allow repeat dosing of patients, which the Company believes may prove to be very important in the potential treatment of Type 1 diabetes."
• "While AAV delivery is a well understood delivery mechanism, the Company believes there could be many benefits to a non-viral delivery system, including the potential for re-dosing patients to optimize treatment."
• "Additionally, there may be no need for immunosuppression since there is no immune response against LNPs."

Industry Context

The announcement highlights Genprex's advancement in non-viral gene therapy delivery, a critical area of innovation in the biotechnology sector. While adeno-associated virus (AAV) vectors are widely used, their limitations, such as potential immunogenicity and challenges with repeat dosing, drive the industry's pursuit of alternative non-viral systems like lipid nanoparticles (LNPs). Successful preclinical proof-of-concept for LNP delivery to specific pancreatic cells (islets of Langerhans) for diabetes treatment positions Genprex at the forefront of developing potentially safer and more flexible therapeutic modalities for chronic conditions like Type 1 diabetes, aligning with broader industry trends towards more targeted and patient-friendly gene therapies.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results for direct comparison to industry benchmarks. The focus is on internal preclinical research findings and the potential advantages of their novel non-viral delivery system over traditional viral methods.

Stakeholder Impact

• Shareholders: Positive impact due to promising preclinical results for a key drug candidate, potentially increasing future value and investor confidence.
• Patients (Type 1 Diabetes): Potential long-term benefit from a novel gene therapy approach that could offer repeat dosing and avoid immunosuppression, improving future treatment options.
• Employees: Positive impact from progress in research and development, potentially securing future projects and stability within the company.
• Regulatory Authorities: The development of novel non-viral delivery systems will be of interest for future regulatory pathways and could influence guidelines for gene therapies.

Next Steps

• Move forward with additional studies for GPX-002 based on the established proof of concept.
• Further evaluate potential next-generation construct optimization for the non-viral delivery system.
• Continue ongoing preclinical studies using an adeno-associated virus (AAV) construct for GPX-002.

Key Dates

Recommendation

Keywords

Gene therapy, Diabetes, Preclinical data, Lipid nanoparticle, GPX-002, Non-viral delivery, Type 1 diabetes, Islets of Langerhans, mRNA, Biotechnology, Genprex